Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Enriqueta Felip(Hebron University), Byoung Chul Cho(Yonsei University), V. Gutiérrez(Hospital Regional Universitario de Málaga), Adlinda Alip(University of Malaya), Benjamin Besse(Université Paris-Saclay), Shaolin Lü(Shanghai Jiao Tong University), Alexander I. Spira(Virginia Cancer Specialists), N. Girard(Université de Versailles Saint-Quentin-en-Yvelines), Raffaele Califano(University of Manchester), S.M. Gadgeel, James Chih‐Hsin Yang(National Taiwan University Hospital), Sadamu YAMAMOTO(Ehime University Hospital), K. Azuma(Kurume University), Yu Jung Kim(Seoul National University Bundang Hospital), K.-H. Lee(Chungbuk National University Hospital), Pongwut Danchaivijitr(Siriraj Hospital), C.G. Ferreira(BioClinica (United States)), Yun Cheng(Jilin Province Tumor Hospital), Mehmet Alı Nahıt Şendur(Ankara Yıldırım Beyazıt University), G.-C. Chang(Chung Shan Medical University Hospital), C.-C. Wang(Kaohsiung Chang Gung Memorial Hospital), K. Prabhash(Tata Memorial Hospital), Y. Shinno, Daniil Stroyakovskiy(Moscow City Oncology Hospital №62), L. Paz-Ares(Universidad Complutense de Madrid), Jerónimo Rafael Rodríguez‐Cid(Hospital Médica Sur), Claire Martin(Instituto Alexander Fleming), M.R. García Campelo(Complexo Hospitalario Universitario A Coruña), H. Hayashi(Kindai University), Danny Nguyen(City Of Hope National Medical Center), P. Tomasini(Inserm), Maya Gottfried(Meir Medical Center), Christophe Dooms(KU Leuven), Antonio Passaro(European Institute of Oncology), Martin Schüler(Essen University Hospital), A.C.Z. Gelatti(Hospital São Lucas da PUCRS), Scott Owen(McGill University), K. Perdrizet(William Osler Health System), S.-H.I. Ou(University of California, Irvine), J.C. Curtin(Janssen (United States)), J. Zhang(Janssen (United States)), Michael Gormley(Janssen (United States)), Tingting Sun(Janssen (United States)), Amey C Panchal(Janssen (United Kingdom)), Marguerite Ennis(Janssen (United States)), E. Fennema(Janssen (United States)), Mahesh Daksh(Janssen (United States)), Seema Sethi(Janssen (United States)), J.M. Bauml(Janssen (United States)), S.-H. Lee(Samsung Medical Center)
Cited by 81Open Access
Abstract
Related Papers
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al.|New England Journal of Medicine|2017|5.2k